Compa ± a de Minas Buenaventura S. A. A. (NYSE: BVN; Lima Stock Exchange: BUE. LM) shall make its call for a convention on the effects of the 3rd quarter of 2020 at:
Leandro Garca Raggio, CEO, along with other members of the leadership team, will participate in the call to review the monetary and operational effects of Buenaventuras for the third quarter of 2020.
The effects of the third quarter will be published on Thursday, October 29, 2020 after the market closes.
To participate in the convention call, check:
If you want to get a call instead of calling, sign in via the link below. Use this option 10 to 15 minutes before the convention call start time:
The convention call can be played for 7 days: United States Free number: 1-877-344-7529 International: 1-412-317-0088 Repeat ID: 10149119
Company description
Compa ± de Minas Buenaventura S. A. A. es the largest publicly traded commodity and valuable metals company in Peru and a leading mining rights holder in Peru. The company is engaged in the exploration, mining development, processing and marketing of gold, silver and other whoofully owned base metals and its participation in Joint Venture Projects. Lately Buenaventura operates several mines in Peru (Orcopampa, Uchucchacua, Julcani, Tambomayo, El Brocal, La Zanja and Coimolache).
The Company owns 43. 65% of Minera Yanacocha SRL (a partnership with Newmont Mining Corporation)
For a published edition of Form 20-F Companys 2019, touch the above or download a PDF record from the Company’s website.
(*) Operations owned 100 percent through Buenaventura
ECS ranked 14th on the list of 250 MSSP MSSP Alert by 2020
Harris Williams advises Indulge Desserts Intermediate Holdings, LLC on sale to Emmi Group
Amazon Web Services (AWS), Hitachi America, Ltd. , Reply, USAA, and others enroll in MOBI in building the movement’s new economy
LOS ANGELES, October 15, 2020 / PRNewswire / – Larger and maximum progressive mobility corporations continue to enroll in MOBI, the Mobility Open Blockchain initiative. New network members enroll in primary car manufacturers, smart city leaders, generation corporations, new companies and other mobility actors who combine to drive progression and adoption of blockchain-based criteria for the mobility ecosystem. These criteria will shape the basis of a protocol-independent legal network that will allow all stakeholders to exchange, enhance and monetize mobility. and transit data.
“We are very pleased that AWS, Hitachi America, Ltd. , Reply, USAA and other mobility opinion leaders see the price of this generation, network and vision,” said MOBI co-founder and COO Tram Vo. “Mobi’s immediate expansion reflects the industry’s point of interest in blockchain generation and the popularity that corporations of all sizes can gain advantages by running in combination to drive adoption. “
Companies are looking to use blockchain and Distributed Records Generation (DLT) to empower and facilitate new facilities for vital consumers and consumers around the world.
“AWS is pleased to enroll in MOBI to work with partners, sponsors, and affiliate members to help set industry criteria for smart mobility blockchain adoption,” said Bill Foy, Automotive Director, Amazon Web Services, Inc. Consumers are running to apply blockchain and distributed accounting technologies to address mobility, source chain, financing and electric vehicle opportunities to the grid. By participating in MOBI, AWS can help consumers apply these new criteria to make transportation greener, more effective, and more affordable through community collaboration. “
Verifiable vehicle travel is used to build a reliable, intelligent and shared mobility ecosystem. MOBI members along the mobility price chain combine to create interoperable, scalable responses that reinvent the business models of the future.
“The mobility industry is undergoing significant adjustments as connected vehicles, autonomous cars, Industry 4. 0, and IoT have an effect on the landscape. By partnering with MOBI, we believe that the deployment of this blockchain initiative will help create mobility ecosystems to drive innovation and improve our core technologies to contribute to our customers’ social, environmental and economic values,” said Dr. Harsha Badarinarayan, Vice President of R
The convergence of several fast-maturation technologies such as AI, IoT, 5G and blockchain allows everything to have a secure identity, be wise and handle other things safely. New sensors, chipsets and electronic parts are being evolved across the industry to facilitate communication of cars connected to other cars and infrastructure (CV2X). Together, these functions will outline the long-term mobility in the smart city.
“Blockchain generation now comes along with IoT, cloud and artificial intelligence to outline the long term of our world,” said Tatiana Rizzante, Reply’s CEO. “At MOBI, we saw the opportunity to work with forward-looking companies, governments and NGOs to make mobility more efficient, greener, safer, and create a more transparent and reliable ecosystem for our consumers and the automotive industry as a whole.
MOBI and its members are working together to drive these inventions and create a longer deadline for mobility. MOBI invites everyone to join us in building the movement’s new economy.
About MOBI
MOBI is a non-profit alliance of many of the world’s largest automakers, as well as start-ups, NGOs, transit agencies, insurers, toll road providers, smart city leaders and generation corporations that run to drive adoption and blockchain advertising criteria, distributed records. and similar technologies.
MOBI creates undeniable blockchain-based criteria to identify cars, other people, and businesses to securely exchange and monetize data, and pay for mobility services, in order to make transportation more efficient, affordable, greener, safer, and less congested. independent of the generation and the ledger. For more information about MOBI membership, please tap Griffin Haskins ([email protected]) or www. dlt. mobi
Media Contact: Kelly Clark, MOBIEmail Communications Manager: [email protected] Twitter: @dltmobi
Related links:
https://www. dlt. mobi/
https://www. dlt. mobi
ROAD TOWN, British Virgin Islands, 15 October 2020 / PRNewswire / – Bitfinex, a virtual token trading platform, and Celsius Network Limited (“Celsius”), the industry-leading cryptocurrency recognition platform, are combining to offer exchange consumers simple access to unmatched Celsius rates to earn praise for their cryptographic holdings.
Together, Bitfinex and Celsius aim at the cryptographic network to stabilize the market by obtaining a passive source of revenue simply by maintaining their currencies. Bitfinex and Celsius have built an integration that will allow Bitfinex consumers to create a portfolio with Celsius and manage it through the Bitfinex Platform. Thanks to their Celsius account, consumers will get a refund of up to 6. 2% APY in Bitcoin, while Ethereum holders will get a rate of up to 9. 65%.
Cryptocurrencies happen where classical banking has been bankrupting its customers for years. Today, banks give very little in terms of interest, falling as low as 0% in 2018 and rarely exceeding 1%. However, banks rate customers exorbitant interest rates on credit cards. The U. S. average for the U. S. and the U. S But it’s not the first time It is 24. 7% with more than $1. 7 trillion in notable customer debt. Meanwhile, in the UK, high-risk lenders rate a TAEG of more than 69% on credit cards. Cryptocurrencies are causing classical banking by getting rid of banks as toll creditors and intermediaries and, in particular, by cutting those maximum rates by decentralizing the classical monetary structures that act in the most productive interests of depositors.
“We expect this offer to attract consumers who have bought Bitcoin as a long-term price reserve and who also need to win with their assets while maintaining them,” said Paolo Ardoino, Bitfinex’s CTO. “Our collaboration with Celsius”. is a component of our project to empower Americans and allow them to take over their finances. “
“Our integration with Bitfinex extends the project and the purpose of any of the corporations to bring the next hundred million people to the cryptographic network and do so while we do it intelligently before doing it right. Celsius’ commitment to rewarding our users with 80% of the price we create is now available to all Bitfinex customers,” said Alex Mashinsky, Celsius CEO.
Bitfinex users who open a Celsius wallet are free to remove their Celsius cryptography at any time, without an era of blocking and no deposit or withdrawal rate. Prizes in Celsius accumulate daily, are composed and paid in Celsius at weekly intervals. a main merit on products that generate the maximum reward that are accompanied by withdrawal restrictions, fees and/or penalties.
APY – annual performance; APR – annual rate Rates on 14/10/2020 and theme to change.
At Bitfinex, founded in 2012, Bitfinex is a virtual token trading platform that provides services for virtual currency investors and global liquidity providers. In addition to a set of complex business functions and mapping equipment, Bitfinex provides access to peer funding. , an OTC market and margin trading for a wide variety of virtual tokens. Bitfinex’s strategy focuses on providing unprecedented support, equipment and inventions to experienced investors and liquidity providers around the world. Visit www. bitfinex. com to be more informed.
Media Contact Joe Morgan, Senior PR Manager, Bitfinex [email protected]
In the fourth Network, Celius Network Limited satisfies the monetary desires of today’s consumers around the world with a high-yield source of income and cheap loans available through a cellular app. Celsius is a blockchain-based market platform where the club provides access to fixed monetary facilities that cannot be obtained through classical monetary institutions. For more information, visit www. celsius. network
Media Contact: [email protected]
Related links:
https://www. bitfinex. com
We are disappointed with the effects of the ASTRAL-2 and ASTRAL-3 studies,” said Mohammad Azab, president and medical director of Astexs. The ASTRAL series of studies was designed to offer a new remedy option to patients with AML or MDS/CMML, and although guadeccitabine is an active drug, studies have not been able to demonstrate statistically impressive final survival results compared to existing healing alternatives. Dr. Azab also added that ASTRAL studies have generated one of the largest clinical and genetic data sets for the medical network of randomized prospective studies using hypomethylating agent therapy (HMA). Guadeccitabine has been linked to better results in some subgroups, but this wants to be validated through additional studies. We are incredibly grateful to all patients, physicians and other physical health professionals, also for the studies and production organizations that have contributed to this global effort.
Guadeccitabine is an experimental compound and lately is approved in any country.
About Guadeccitabine
Guadeccitabine is a next-generation DNA speculation agent. 1,2 Guadeccitabine was rationally designed to be resistant to degradation through cytidine deaminase, prolonging the tumor’s mobile exposure to the active metabolite, decitabine, thus ensuring greater absorption of deciasine into DNA quickly. , through the action of decitinate, inhibits DNA methyltransferase (DNMT), with the prospect of opposing aberrant DNA methylation, an epigenetic replacement characteristic of many cancerous mobiles, and can repair the expression of tumor-related antigenic and silent tumor suppressive genes . 4 Through this reexpression of silenced genes, guadeccitabine would possibly have the possibility of sensitizing tumor mobiles to other anticancer agents5Array6 ,7, adding immunotherapeutics8, as well as resensitizing cancerous mobiles in the past resistant to chemotherapy7.
Guadeccitabine designed to be administered subcutaneously as solid formulas at low volume.
Astex and Otsuka announced in July 2018 that the global randomized ASTRAL-1 test of guadecitabine in adults with untreated AML in the past and that they were not eligible for extensive induction chemotherapy (https://www. clinicaltrials. gov NCT02348489) was unsuccessful at its main endpoints.
Guadeccitabine is also being evaluated in more than 20 trials funded through researchers in malignant hemopathies and counterfeit tumors, either in monasticity and in mixture with chemopia or immunoapia.
About the ASTRAL-2 Study
The ASTRAL-2 exam (https://www. clinicaltrials. gov NCT02920008) evaluated the efficacy and protection of guadecitabine in adults with past AML treated with initial induction therapy, a popular extensive chemotherapy regimen, comprising cytarabine and an anthracycline, and that was refractory to initial induction (refractory number one) or relapsed after such initial induction with or without prior hematopoietic motile transplantation. The review randomized 302 patients from 98 study sites in 15 countries around the world. They screened patients randomized 1: 1 to obtain guadecitabine in cycles of 28 days, administered subcutaneously for 10 days in cycle 1, then 10 or five days in cycle 2 and five days from cycle 3, or doctor’s choice of (i) a maximum intensity regimen comprising a mean or maximum dose of cytarabine; mitoxantrone, etoposide and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG / FLAG-Ida); (ii) a low intensity regimen comprising a low dose of cytarabine or azacitidine or decitabine; and (iii) The best supportive care only. In addition to the number one endpoint of OS, the review evaluated several secondary endpoints, adding event-free survival, long-term survival, number of days alive and out-of-hospital, disease reaction, transfusion independence rate , total reaction rate, total composite hematopoietic mobile transplantation rate, duration of complete reaction, quality of life, occurrence and severity of adverse events, and all-cause mortality at 30 and 60 days.
About the ASTRAL-3 Study
The ASTRAL-3 (https://www. clinicaltrials. gov NCT029073five9) test assessed the efficacy and protection of guadecitabine in adults with MDS or CML in the past treated with hypometicant. The test randomized 417 patients from 91 research sites in 14 countries. all over the world. Examine randomized patients 2: 1 to obtain in 28-day subcutaneous guadeccitabine cycles for five days or the doctor’s selection of (i) low-dose citarabine; (ii) extensive chemotherapy (IQ) 7 3 popular citarabine and an anthracycline, or mitoxantrone; and (iii) Better supportive care only. In addition to the GS-one assessment criterion, the test evaluated several secondary parameters, adding transfusion independence, complete spinal cord reaction rate, survival rate, leukemia survival, number of days in and out of the hospital, reaction to the disease, duration of reaction, number of transfusions, health-related quality of life Organize the onset and severity of adverse occasions and mortality from all causes at 30 and 60 Days.
About Acute Myeloid Leukemia
AML is the maximum non-unusual form of acute leukemia in adults. 9 An estimated 19,940 new cases of AML are expected in the United States in 202010 and an estimated 11,180 patients will die of AML in the United States by 202010. 60 to 80, the percentage of AML patients under the age of 60 may discharge a complete reaction with popular extensive induction chemotherapy. worse, and those patients want effective, less poisonous therapies.
Like myelodysplastic syndromes and myelonocytic leukemia
Myelodysplastic syndromes are a heterogeneous organization of mobile hematopoietic stem disorders characterized by dysplastic adjustments in mobile myeloid progenitors, erythroids and megakaryocytes, and related to cytooperas affecting one or more of the 3 lines. It is estimated that the occurrence of MDS in the United States is 10,000 cases. consistent with the year, the disease is thought to be underdiagnosed. 12,13 Prevalence has been estimated between 60,000 and 170,000 in the United States14 MDS can progress to acute myeloid leukemia in one third of patients15. ; patients die from citopenia-related headaches (infections and bleeding) or from transformation into AML.
CML is a clonal hematopoietic malignant tumor characterized by the accumulation of monocytes in the bone marrow and blood. The occurrence of CML in the United States is approximately 1,100 new cases consistent with year 16 and CML can become AML by 15% to 30%. patients. 17
The oral hypomethylating agents decitabine, azacitidine, and decibine and ceaazuridine are FDA approved for the remedy of intermediate and high risk MDS and CMML. 18,19,20 survival from failure is less than six months. 21
About Astex Pharmaceuticals and Otsuka Pharmaceutical
Astex is a leader in the discovery and progression of cutting-edge drugs, committed to the fight against cancer. Astex develops an exclusive pipeline of new treatments and has several products in progression through collaborations with leading pharmaceutical companies. Astex is a wholly subsidiary of Otsuka Pharmaceutical Co. , Ltd. , in Tokyo, Japan.
Otsuka Pharmaceutical is a global fitness company with business philosophy: Otsuka “creates new products for greater fitness in the world”. Otsuka researches, develops, manufactures and markets original and cutting-edge products, with a focus on prescription drugs for disease remedy. and nutraceuticals for the maintenance of daily fitness.
For more information about Astex Pharmaceuticals, Inc. , visit: https://www. astx. com
For more information about Otsuka Pharmaceutical, visit: https://www. otsuka. co. jp/en/
references
1. Kantarjian HM, Roboz GJ, Kropf PL, et al. Guadecitabine (SGI-110) in treatment-naïve patients with acute myeloid leukemia: phase 2 effects of a multicenter, randomized, phase 1/2 trial. Lancet Oncol 2017; 18 (10): 1317-26. 2. Roboz GJ, Kantarjian HM, Yee KWL et al. Dose, time, protection and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer 2018; 124 (2): 325-34. 3. Issa JJ, Roboz G, Rizzieri D et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukemia: A multicenter, randomized, dose escalation phase 1 examines Lancet Oncol 2015; 16 (nine): 10ninenin-110. 4. Griffiths EA, Choy G, Redkar S, Taverna P, Azab M, Karpf AR. SGI-110: Oncolytic DNA methyltransferase inhibitor. Drugs Future 2013; 38 (8): 535-43. 5. Cebar Kuang Y, El-Khoueiry A, Taverna P, Ljungman M, Neamati N. Guadecitabine (SGI-110) sensitizes hepatocellular carcinoma cells to oxaliplatin. Mol Oncol 2015; nine (nine): 17ninenin-814. 6. Srivastava P, Paluch BE, Matsuzaki J, et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res 2014; 38 (11): 1332-41. 7. Fang F, Munck J, Tang J et al. The new SGI-110 small molecule DNA methylation inhibitor as a chemosensitizer in ovarian cancer. Clin Cancer Res 2014; 20 (24): 6504-16. 8. Lindblad KE, Goswami M, Hourigan CS, Oetjen KA. Immunological effects of hypomethylating agents. Hematology Expert Review 2017; 10 (8): 745-52. nine. De Kushkovsky I, Abdul-Hay M. “Acute myeloid leukemia: a comprehensive review and update from 2016”. Blood Cancer J. 2016; 6 (7): e441. 10. Air conditioning company. Key Statistics on Acute Myeloid Leukemia 2018 [Available at: https://www. cancer. org/cancer/acute-myeloid-leukemia/about/key-statistics. html. 11. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and control of acute myeloid leukemia in adults: 2017 ELN recommendations from a qualified foreign panel. Some blood. 2017; 12nine (4): 424-47. 12. García-Manero G. Myelodysplastic syndromes: 2015 update on diagnosis, stratification and risk management. Am J Hematol 2015; nine0 (nine) 831-841. 13. Ma X, makes M, Race A, Mayne ST. Myelodysplastic Syndromes: Onset and Survival in the United States. Cancer 2007; 10nine (8): 1536-1542. 14. Cogle C. Incidence and burden of myelodysplastic syndromes. Curr Hematol Malig Rep 2015; 10 (3): 272-281. 15. Shukron O, Vainstein V, K¼ndgen A, Germing U, Agur Z. Analysis of the transformation of myelodysplastic syndrome into secondary acute myeloid leukemia: a giant patient database. Am J Hematol 2012; 87: 853 “860. 16. What are the key statistics about chronic myelomonocytic leukemia? American Cancer Society website. https://www. cancer. org/cancer/chronic-myelomonocytic-leukemia/about/key-statistics. html. Accessed August 26, 2020. 17. About Chronic Myelomonocytic Leukemia (CMML). Cancer Research UK website. https://www. cancerresearchuk. org/about-cancer/other-conditions/chronic-myelomonocytic-leukaemia-cmml/about. Accessed August 26, 2020. 18. See: https://www. accessdata. fda. gov/drugsatfda_docs/label/2018/0217nine0s021lbl. pdf 1nine. See: https://www. accessdata. fda. gov/drugsatfda_docs/label / 2008 / 0507nine4s011lbl. pdf 20. See: https://www. accessdata. fda. gov/drugsatfda_docs/label/2020/212576s000lbl. pdf 21. Steensma, PD Current Treatment Algorithm for Myelodysplastic Syndromes 2018. Blood Cancer Journal 8, 47 (2018). https://doi. org/10. 1038/s41408-018-0085-4
ROAD TOWN, British Virgin Islands, 15 October 2020 / PRNewswire / – Bitfinex, a virtual token trading platform and Celsius Network . . .
Amazon Web Services (AWS), Hitachi America, Ltd. , Reply, USAA, and others enroll in MOBI in building motionArray’s new economy.
Astex Pharmaceuticals, Inc. , a member of the Otsuka Business Group, and Otsuka Pharmaceutical Co. , Ltd. , announced their first effectsArray. .
Roku, Inc. (NASDAQ: ROKU) issued a verdict today in MV3 Partners LLC v. Roku Inc. Heard . . .
Law firm Howard G. Smith announces an investigation on behalf of Vasta Platform, Ltd. (“Vasta” or the “Company”) (NASDAQ: . . .
PennyMac Financial Services, Inc. (NYSE: PFSI) (the Company) announced the value of its global equity of $ 150 million provided by Array.
Orchid Island Capital, Inc. (NYSE: ORC) announced that the Board of Directors (the Board) has declared per month moneyArray. .
Cushman
Bernstein Liebhard, a nationally renowned investor rights law firm, announces that an action of elegance of securities has been presented at Array.
Majesty and Elize are the founders of Evo Fund; an ESG fund and an equity company that develops real estate . . .
Mandatory cookies are surely for the proper functioning of the site. This category includes only cookies that provide the fundamental capability and security features of the website. These cookies do not purchase any non-public information.